2023年6月5日

來源:披露:。克裏內報告接受贈款從阿斯利康,勃林格殷格翰的發言,Broncus,基耶西,烏鴉座,基因泰克,基列,葛蘭素史克,Fisher-Paykel醫療、莉莉,NIH-NHLBI,諾華,奧林巴斯,PA-DOH,輝瑞,珠兒,PneumRx, Pulmonx, Regeneron,羅氏公司和啟示作用;從Almirall顧問費用,阿斯利康,Broncus BTG, CSA醫療、葛蘭素史克、EOLO,直觀,離子,Mereo, Nuvaira, PneumRx, Pulmonx, Regeneron和賽諾菲;和股票的興趣自由流動醫療和胸膜動力學。主題添加到郵件提醒收到一封電子郵件在發布新文章時請提供您的電子郵件地址來接收電子郵件當張貼新文章。請稍後再試。如果你繼續這個問題請聯係customerservice@slackinc.com。回到Healio肺減容治療改善患者FEV1肺氣腫。嚴重不良事件的數量在接受治療與控製。華盛頓——嚴重肺氣腫肺功能改善了患者在接受治療後5年內支持截止閥係統中,根據研究發表於美國胸科協會國際會議。傑拉德j。克裏內“支氣管鏡肺減容手術是一個持久的治療反應和最佳藥物治療相比,”傑拉德j。克裏內,醫學博士FACP, FACCP,聖殿肺中心主任和椅子和胸醫學與外科教授劉易斯Katz天普大學醫學院,告訴Healio。 Patients with severe emphysema had improved lung function at 5 years after receiving treatment with a support expiration valve system, according to research presented at the American Thoracic Society International Conference. Image: Adobe Stock Criner and colleagues evaluated 172 patients with severe emphysema in the EMPROVE trial to see if the Spiration Valve System (Olympus) was safe and effective over 5 years. As Healio previously reported , the Spiration Valve System showed sustained clinically significant benefit in health-related quality of life at 2 years in patients with severe emphysema. To assess differences in lung function from baseline over the span of 5 years, researchers utilized the mixed-effects model. Additionally, researchers calculated the rate of serious adverse events by finding out how many events took place 6 months after the procedure and dividing that by the remaining cumulative follow-up patient-years. Of the total cohort, 113 patients received Spiration Valve System treatment and 59 patients were a part of the control group. Following the procedure, patients demonstrated a 0.1098 L increase (P < .001) in lung function, or FEV1; however, this measure was found to fall by 0.044 L per year (P < .001) in both these patients and control patients, according to the abstract. With the two groups showing a comparable rate of decline, researchers assumed that disease progression was occurring at a “steady rate,” signaling that patients who underwent the valve placement procedure instantly got approximately 2.5 years of improvement in FEV1. When evaluating all serious adverse events, the rate was comparable between both sets of patients, with a rate of 0.6, or 210 events in 5 years, in the treatment group, and 0.48, or 35 events in 2 years, in the control group since researchers only followed control patients for 2 years. Notably, the rate of pneumothorax in the treatment group was 0.21, or 75 events in 5 years, and 0 in the control group, according to the abstract. In terms of increasing lung function, researchers deemed the treatment “safe and durable” based on the above findings. “This affirms the prior data with use of lung volume reduction surgery and non-controlled cohort follow-ups post bronchoscopic lung volume reduction that patients have a durable treatment response,” Criner told Healio. Read more about